Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 12Myeloproliferative Disorders 2Leukemia, Biphenotypic, Acute 2Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Patient Preference 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Leukemia, Myeloid, Chronic-Phase 1GATA2 Deficiency 1Colorectal Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Patient Preference × decitabine and cedazuridine drug combination × Other hematologic neoplasm × Clear all
NCT05883956 2025-03-20

PREFER-HMA

Otsuka Australia Pharmaceutical Pty Ltd

Phase 3 Active not recruiting
13 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡